SCHEMBL209269

SCHEMBL209269

CN(C)C1(Cc2ccc(Cl)cc2)CCC(NC(=O)CCC(=O)N2CCSCC2)CC1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.41
EPHX2 P34913 1/20 0.40
ATF4 P18848 1/20 0.40
HPGD P15428 2/20 0.39
SSTR1 P30872 1/20 0.39
SSTR4 P31391 1/20 0.39
POLB P06746 1/20 0.39
SIGMAR1 Q99720 1/20 0.39
GAA P10253 2/20 0.38
MAPK1 P28482 1/20 0.38
EPHX1 P07099 1/20 0.37
ALDH1A1 P00352 4/20 0.37
KMT2A Q03164 2/20 0.37
MEN1 O00255 1/20 0.37
HSD17B10 Q99714 1/20 0.36
AVPR1A P37288 1/20 0.36
DPP4 P27487 1/20 0.36
DPP7 Q9UHL4 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL208277 0.89 SMN1; SMN2 (0.47) LMNAEPHX2ATF4HPGDSSTR1
SCHEMBL208174 0.89 SIGMAR1 (0.43) EPHX2HPGDSSTR1SSTR4SIGMAR1
SCHEMBL205723 0.86 ALDH1A1 (0.45) LMNAATF4POLBALDH1A1KMT2A
SCHEMBL205853 0.85 HPGD (0.40) LMNAEPHX2ATF4HPGDSSTR1
SCHEMBL207812 0.84 MAPT (0.48) LMNAPOLBMAPK1ALDH1A1KMT2A
SCHEMBL205265 0.84 KMT2A (0.46) LMNAHPGDSSTR1SSTR4POLB
SCHEMBL206987 0.83 POLB (0.56) LMNAEPHX2HPGDPOLBGAA
SCHEMBL206876 0.83 MGLL (0.43) LMNAPOLBALDH1A1KMT2AMEN1
SCHEMBL4072326 0.82 SIGMAR1 (0.49) LMNASIGMAR1MAPK1KMT2AMEN1
SCHEMBL206115 0.82 NPC1 (0.38) LMNAATF4SSTR1SSTR4MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088763-B2 e.g. N-[1-(2,6-dichloro-benzyl)-pyrrolidin-3-yl]-N'-[4-dimethylamino-4-(4-methyl-benzyl)-cyclohexyl]-succinamide; noradrenaline and serotonin reuptake ihibitor; opioid ORL-1 receptor ligand; analgesic, antidepressant, anxiolytic agent, neurodegenerative diseases GRUENENTHAL GMBH (DE) 2012-01-03 US claimed
EP-1745010-B1 SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES GRUENENTHAL GMBH (DE) 2009-08-05 EP claimed
US-20070112007-A1 Cyclohexyl-1, 4-diamine compounds GRUENENTHAL GMBH (DE) 2007-05-17 US claimed
US-8088763-B2 e.g. N-[1-(2,6-dichloro-benzyl)-pyrrolidin-3-yl]-N'-[4-dimethylamino-4-(4-methyl-benzyl)-cyclohexyl]-succinamide; noradrenaline and serotonin reuptake ihibitor; opioid ORL-1 receptor ligand; analgesic, antidepressant, anxiolytic agent, neurodegenerative diseases GRUENENTHAL GMBH (DE) 2012-01-03 US disclosed
EP-1745010-B1 SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES GRUENENTHAL GMBH (DE) 2009-08-05 EP disclosed
US-20070112007-A1 Cyclohexyl-1, 4-diamine compounds GRUENENTHAL GMBH (DE) 2007-05-17 US disclosed
EP-1745010-A1 SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES Grünenthal GmbH (DE) 2007-01-24 EP disclosed
WO-2005110974-A1 SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES Grünenthal GmbH (DE) 2005-11-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070112007-A1 Cyclohexyl-1, 4-diamine compounds PKD1, DDC, DPYD LMNA 1995/4885EPHX2 1203/4885ATF4 1370/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.